April 2016

New Product - Imlygic

Imlygic (talimogene laherparepvec (rmv)) is an oncolytic immunotherapy derived from HSV-1. Imlygic has been modified to replicate within tumours and to produce the immune stimulatory protein GM-CSF. Imlygic causes lytic tumour cell death and release of tumour derived antigens and GM-CSF, which together promote a systemic antitumour immune response. Imlygic is indicated as monotherapy for the treatment of melanoma in patients with unresectable cutaneous, subcutaneous or nodal lesions after initial surgery. Imlygic is contraindicated with severe immunocompromise (e.g. severe congenital or acquired cellular and/or humoral immune deficiency). Imlygic is available as 1 million PFU/1 mL (initial dose) and 100 million PFU/1 mL (subsequent doses) in single use vials of 1.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au